The effect of physical therapy in the treatment of patients with cervical dystonia with or without concomitant use of botulinum toxin

Ivona Stanković; Hristina Čolović; Vesna Živković; Jelena Stamenović; Anita Stanković; Dragan Zlatanović; Danijela Živković; Tamara Stanković

doi:10.2298/VSP161115016S

Ivona Stanković Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
Hristina Čolović Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
Vesna Živković Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
Jelena Stamenović University of Niš, Faculty of Medicine, Niš, Serbia
Anita Stanković Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
Dragan Zlatanović Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
Danijela Živković University of Niš, Faculty for Sports and Physical Education, Niš, Serbia
Tamara Stanković University of Niš, Faculty of Medicine, Niš, Serbia

DOI: https://doi.org/10.2298/VSP161115016S

Keywords: cervical dystonia, primary;, physical therapy modalities;, botulinum toxins;, classification.

Abstract

Background/Aim. Botulinum toxin is a basic, recommended method of treatment in controlling cervical dystonia (CD). Physical therapy has limited effect due to the nature of the disease that is a result of a disorder in structures and relationships of the basal ganglia. The aim of this study was to analyze the effect of physical therapy applied as monotherapy, or with parallel application of botulinum toxin in patients with CD. Methods. Randomized controlled clinical pilot study included 14 patients diagnosed with idiopathic CD. All patients were initially assessed by using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) and Torticollis Rating Scale (Tsui scale). In the control group, composed of 5 patients, the treatment included only physical therapy. The experimental group (9 patients) was first given botulinum toxin, and physical therapy was applied after five days. Physical therapy was conducted five times a week in the period of two weeks at the Clinic. Patients of both groups were instructed to continue with the physical therapy at home. The effects of treatment were analyzed after 1, 3 and 6 months using TWSTRS and Tsui scale. Results. At the beginning of the investigation, the differences in TWSTRS and Tsui scale between the groups were not significant. In the control group, after 1 month, significant improvement was achieved in all three parts of the TWSTRS. After 3 and 6 months, the effects of physical therapy were reduced to control levels. In the experimental group, highly significant increase of all parameters of TWSTRS was noted after 1, 3 and 6 months. In the control group, highly significant decrease of changes in Tsui scale was noticed only after one month while in the experimental group, it was maintained after 3 and 6 months. Conclusion. Application of physical therapy provides a significant improvement in disease severity, but the effect is better and of longer duration when combined with the botulinum toxin.

References

REFERENCES

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006; 67(12): 2233–5.

de Carvalho AP, Ozelius LJ. Classification and genetics of dys-tonia. Lancet Neurol 2002; 1(5): 316–25.

Gross AR, Hoving JL, Haines TA, Goldsmith CH, Kay T, Aker P, et al. Cervical overview group. Manipulation and mobilisation for mechanical neck disorders. Cochrane Da-tabase Syst Rev 2004; (1): CD004249.

Fabbri M, Superbo M, Defazio G, Scaglione CL, Antelmi E, Basini G, et al. Quality of life in patients with craniocervi¬cal dysto-nia: Italian validation of the "Cervical Dystonia Impact Pro-file (CDIP-58)" and the "Craniocervical Dysto¬nia Question-naire (CDQ-24)". Neurol Sci 2014; 35(7): 1053–8.

Jinnah HA, Factor SA. Diagnosis and Treatment of Dysto¬nia. Neurol Clin 2015; 33(1): 77–100.

Krauss JK, Toups EG, Jankovic J, Grossman RG. Sympto¬matic and functional outcome of surgical treatment of cer¬vical dys-tonia. J Neurol Neurosurg Psychiatr 1997; 63(5): 642–8.

Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic Review and Meta Analysis of the Duration of Clinical Ef¬fect of Onabotulinumtoxin A in Cervical Dystonia. BMC Neurol 2014; 14: 91.

Benecke R, Dressler D. Botulinum toxin treatment of axial and cervical dystonia. Disabil Rehabil 2007; 29(23): 1769–77.

Comella CL. The treatment of cervical dystonia with botuli-num toxins. J Neural Transm 2008; 115(4): 579–83.

Pappert EJ, Germanson T. Myobloc/Neurobloc European Cer-vical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Dis¬ord 2008; 23(4): 510–7.

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dysto¬nia: a consensus update. Mov Disord 2013; 28(7): 863–73.

Crowner BE. Cervical dystonia. Disease profile and clinical management. Phys Ther 2007; 87(11): 1511–26.

Zetterberg L, Halvorsen K, Färnstrand C, Aquilonius SM, Lind-mark B. Physiotherapy in cervical dystonia: Six ex¬perimental single-case studies. Physiother Theory Pract 2008; 24(4): 275–90.

Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warn-er TT. Patient Based Outcomes of Cervical Dystonia: A Re-view of Rating Scales. Mov Disord 2004; 19(9): 1054–9.

Charles DP, Adler CH, Stacy M, Comella C, Jankovic J, Manack AA, et al. Cervical dystonia and pain: Characteris¬tics and treatment patterns from CD PROBE (Cervical Dystonia Pa-tient Registry for Observation of OnabotulinumtoxinA Effi-cacy). J Neurol 2014; 261(7): 1309–19.

Jen M, Kurth H, Iheanacho I, Dinet J, Gabriel S, Wasiak R, et al. Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: A meta-analysis of baseline patient-level clinical trial data. J Med Econ 2014; 17(11): 803–9.

Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchower¬sky O. Long-term efficacy of botulinum toxin A in treat¬ment of var-ious movement disorders over a 10-year pe¬riod. Mov Disord 2002; 17(6): 1288–93.

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin ef-ficacy, safety, and immunogenicity. Mov Disord 2005; 20(5): 592–7.

Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55(5): 732–5.

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60(7): 1186–8.

Swope D, Barbano R. Treatment recommendations and prac¬tical applications of botulinum toxin treatment of cer¬vical dysto-nia. Neurol Clin 2008; 26(Suppl 1): 54–65.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low im¬munogenicity by mouse protection assay. Mov Disord 2008; 23(10): 1353–60.

Gregori B, Agostino R, Bologna M, Dinapoli L, Colosimo C, Accornero N, et al. Fast voluntary neck movements in pa¬tients with cervical dystonia: A kinematic study before and after therapy with botulinum toxin type A. Clin Neuro¬physiol 2008; 119(2): 273–80.